Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (OTCQB: PRVCF) is a health sciences company that regularly issues news on its preventive and curative therapy programs, corporate developments and proposed corporate transactions. Company news provides insight into its research pipeline, including dual gene therapy for diabetes and obesity, the Sol-Gel nose-to-brain (N2B) delivery platform, Nature Identical™ peptide programs, nonaddictive analgesic peptide candidates and concussion-related therapeutic concepts.
Recent announcements have highlighted appointments of experienced scientific and industry advisors, such as corporate advisors and technology leaders who bring backgrounds in drug discovery, metabolic disease research, molecular genetics and clinical development. These updates help investors and observers understand how PreveCeutical is building expertise around its programs and advancing toward development and potential commercialization.
News releases also cover the evolution of the Sol-Gel N2B platform, including a program aimed at delivering dopamine and/or its precursor L-Dopa directly to the brain in the context of Parkinson’s disease. The company has described this platform as designed to bypass the blood-brain barrier, with the goal of improving drug bioavailability and reducing systemic side effects.
Another recurring theme in PreveCeutical’s news is its relationship with BioGene Therapeutics Inc., a wholly owned subsidiary focused on metabolic health and gene-based treatments. The company has announced a proposed plan of arrangement under which it intends to distribute up to 12,000,000 BioGene common shares to PreveCeutical shareholders, and meeting materials and court orders related to this arrangement have been reported in its news flow.
Investors and researchers following PRVCF news can use this page to review updates on research milestones, advisory and executive appointments, meeting dates, and the progress of the proposed BioGene share distribution, all drawn from official company announcements.
PreveCeutical (OTCID: PRVCF) elected to adopt semi-annual financial reporting under Coordinated Blanket Order 51-933, moving from quarterly to semi-annual reporting for eligible CSE venture issuers.
The company will not file interim reports and MD&A for Q1 ending March 31, 2026 and Q3 ending September 30, 2026. PreveCeutical will continue to file audited annual financial statements (due within 120 days of December 31, 2025) and six-month interim reports (due within 60 days of June 30, 2026). The company confirms eligibility with annual revenues under $10 million and a clean 12-month continuous disclosure record.
PreveCeutical Medical (OTCQB: PRVCF) appointed Dr. Raj S. Pruthi to its Board of Directors on March 30, 2026. Dr. Pruthi brings 20+ years in academic medicine and pharma, plus experience leading clinical programs, regulatory interactions with FDA and EMA, and capital markets work.
He currently serves as Chief Medical Officer at Relmada Therapeutics and has led late‑stage development, financing rounds totaling about $260 million, and programs advancing toward Phase 3.
BioGene Therapeutics (OTCQB: PRVCF) appointed Raj S. Pruthi, MD, MHA, FACS, as a director on March 12, 2026.
Dr. Pruthi will lead clinical strategy for gene therapy programs targeting diabetes and obesity. The company granted him 100,000 options at $5.00 and 500,000 RSUs with four-year vesting through March 10, 2029.
PreveCeutical Medical (OTCQB: PRVCF) received allowance of Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", covering novel cyclized dynorphin analogues for pain therapy.
Grant is expected in Q2 2026, with Canadian exclusivity until January 2040, joint ownership with The University of Queensland, and a broader patent family pending in the US, Europe, and Australia.
PreveCeutical (OTCQB: PRVCF) filed an International (PCT) patent application (PCT/US2026/014110) on February 5, 2026 for "Delivery of CNS-active therapeutic agents." The filing covers methods and formulations for delivering dopamine and other CNS-active drugs directly to the brain, targeting Parkinson's disease and other CNS disorders. The company notes potential to bypass L-dopa limitations but states it is not making clinical claims and that outcomes remain uncertain.
PreveCeutical Medical (OTCQB:PRVCF) has announced the filing and mailing of meeting materials for its upcoming annual general and special meeting scheduled for October 10, 2025. The meeting will address a proposed arrangement with BioGene Therapeutics, involving a spin-out of 12 million BioGene common shares to PreveCeutical shareholders on a pro rata basis.
The company has received an interim order from the British Columbia Supreme Court on September 9, 2025, authorizing the meeting. The meeting materials are now available on SEDAR+ and the company's website.
BioGene Therapeutics Inc., a subsidiary of PreveCeutical Medical Inc. (OTCQB: PRVCF), has appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025. Dr. Tavares brings 30 years of experience in drug discovery and development, previously serving as President and CEO of ChemoGenics BioPharma and Group Manager at GlaxoSmithKline.
His notable achievements include leading the development of Trilaciclib and completing Phase 3 trials of Lerociclib, a CDK4/6 inhibitor. Dr. Tavares holds a PhD in Organic Chemistry and has extensive experience in developing small-molecule inhibitors, having championed over 15 metabolic targets throughout his career.
PreveCeutical Medical (OTCQB: PRVCF) has announced the appointment of Dr. Kamal Albarazanji as Senior Director of Metabolic Research at its subsidiary BioGene Therapeutics, effective August 18, 2025. Dr. Albarazanji brings extensive experience in metabolic research, having previously served as a Senior Scientist in Cardiovascular & Metabolic Diseases.
Dr. Albarazanji's background includes significant work at SmithKline Beecham (now GSK) on various therapeutic programs, including renin inhibitors and insulin sensitizers. He holds multiple patents and has authored over 20 peer-reviewed publications in prestigious journals. His expertise spans in vivo pharmacology, target validation, and translational research, with particular focus on metabolic diseases, obesity, and diabetes treatments.
PreveCeutical Medical (OTCQB: PRVCF) has rescheduled its annual general and special meeting from August 15 to September 5, 2025. At the meeting, shareholders will vote on key matters including director elections and the appointment of Davidson & Company LLP as auditors.
A significant proposal involves the distribution of up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders through a plan of arrangement. This strategic move will result in shareholders owning stakes in both companies: BioGene, focusing on Dual Gene Therapy development, and PreveCeutical, continuing its work on preventive and curative therapies using organic products.
PreveCeutical Medical Inc. (OTCQB: PRVCF) has appointed Dr. Francis Tavares as Chief Technology Officer, effective June 27, 2025. Dr. Tavares brings over three decades of experience in organic and medical chemistry, and drug discovery to the company.
Dr. Tavares most recently served as President and CEO of ChemoGenics BioPharma, where he led drug discovery initiatives resulting in the commercialization of Trilaciclib and successful Phase 3 clinical trials of Lerociclib, a CDK4/6 inhibitor. His career includes significant achievements at GlaxoSmithKline, where he received the Excellence in Science Award in 2004, and the successful establishment of ChemoGenics BioPharma.
The appointment strengthens PreveCeutical's leadership team as the company continues its development of preventive and curative therapies using organic and nature-identical products.